PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Carcinogenesis

• Publication date

  2013-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/carcin/bgs393PMID 23275151PMCID PMC3616665
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis.

  2013cited by this paper
• Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells

  2013cited by this paper
• Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.

  2012cited by this paper
• Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

  2012cited by this paper
• CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.

  2011cited by this paper
• PARP inhibitor treatment in ovarian and breast cancer.

  2011cited by this paper
• The knock-down of ERCC1 but not of XPF causes multinucleation.

  2011cited by this paper
• COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION

  2011cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

  2011cited by this paper
• MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers.

  2011cited by this paper
• Drug Inhibition Profile Prediction for NFκB Pathway in Multiple Myeloma

  2011cited by this paper
• Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

  2011cited by this paper
• PARP inhibition induces BAX/BAK‐independent synthetic lethality of BRCA1‐deficient non‐small cell lung cancer

  2011cited by this paper
• Iniparib in metastatic triple-negative breast cancer.

  2011cited by this paper
• Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells.

  2010cited by this paper
• PARP inhibition: PARP1 and beyond

  2010cited by this paper
• The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.

  2010cited by this paper
• Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer

  2010cited by this paper
• Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.

  2010cited by this paper
• The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010cited by this paper
• The XPA-binding domain of ERCC1 Is Required for Nucleotide Excision Repair but Not Other DNA Repair Pathways*

  2009cited by this paper
• PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombination

  2009cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• Photoaffinity labeling reveals nuclear proteins that uniquely recognize cisplatin-DNA interstrand cross-links.

  2009cited by this paper
• The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links

  2009cited by this paper
• Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression

  2009cited by this paper
• Cisplatin sensitivity is related to late DNA damage processing and checkpoint control rather than to the early DNA damage response.

  2009cited by this paper
• Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

  2008cited by this paper
• High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

  2008cited by this paper
• A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.

  2008cited by this paper
• Preclinical versus clinical drug combination studies

  2008cited by this paper
• BRCA1: a new genomic marker for non-small-cell lung cancer.

  2008cited by this paper
• Platinum Resistance: The Role of DNA Repair Pathways

  2008cited by this paper
• A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity.

  2008cited by this paper
• ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

  2007influential reference
• Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.

  2007cited by this paper
• Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.

  2007cited by this paper
• Clonogenic assay of cells in vitro

  2006cited by this paper
• CISCA (cisplatin vs. carboplatin) meta-analysis: An individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC).

  2006cited by this paper
• DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

  2006cited by this paper
• Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin.

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Cellular processing of platinum anticancer drugs

  2005cited by this paper
• Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks

  2004cited by this paper
• Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.

  2003cited by this paper
• Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity.

  1996cited by this paper
• Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3.

  1993cited by this paper
• Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells.

  1988cited by this paper
• (ADP-ribose)n participates in DNA excision repair

  1980cited by this paper

• Determination of veliparib metabolic stability in the human liver microsomes using a hydrophilic interaction UPLC-MS/MS quantitative method: greenness assessment with an in silico study for ADME, DEREK alarms and metabolic lability.

  2025cites this paper
• Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies

  2025cites this paper
• Denosumab Regulates Titanium Particles‐Induced Macrophages Inflammation and Osteolysis by Targeting the ST18/PARP1 Interaction

  2025cites this paper
• PARP inhibition increases sensitivity to cisplatin in non-small-cell lung carcinoma via the induction of TET-dependent hydroxymethylation

  2025cites this paper
• PJ34 prevents cisplatin-induced hair cell loss via inhibition of PARP-1–AIF parthanatos

  2025cites this paper
• Inhibition of nucleotide excision repair proteins associated with cancer chemotherapy.

  2025cites this paper
• Establishment and validation of an innovative UPLC-MS/MS approach for quantitation and pharmacokinetics of veliparib in rat plasma

  2024cites this paper
• Aurora Kinase A Inhibition Potentiates Platinum and Radiation Cytotoxicity in Non-Small-Cell Lung Cancer Cells and Induces Expression of Alternative Immune Checkpoints

  2024influential citation
• Unveiling Novel ERCC1–XPF Complex Inhibitors: Bridging the Gap from In Silico Exploration to Experimental Design

  2024cites this paper
• Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review

  2024cites this paper
• Cisplatin in the era of PARP inhibitors and immunotherapy.

  2024cites this paper
• Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells

  2023cites this paper
• PARP Inhibitors and Proteins Interacting with SLX4

  2023cites this paper
• Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control.

  2023cites this paper
• Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system

  2022cites this paper
• Cancer cell-autonomous overactivation of PARP1 compromises immunosurveillance in non-small cell lung cancer

  2022cites this paper
• The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects

  2022cites this paper
• Effect of the PARP inhibitor veliparib on germ cell tumor cell lines

  2022cites this paper
• The molecular landscape of pancreatic ductal adenocarcinoma.

  2022cites this paper
• Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study.

  2021cites this paper
• Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors

  2021cites this paper
• A375 melanoma cells are sensitized to cisplatin-induced toxicity by a synthetic nitro-flavone derivative 2-(4-Nitrophenyl)-4H-chromen-4-one through inhibition of PARP1

  2021cites this paper
• A newly established monoclonal antibody against ERCC1 detects major isoforms of ERCC1 in gastric cancer.

  2021cites this paper
• Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.

  2021cites this paper
• PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.

  2021cites this paper
• Genetic alterations and their therapeutic implications in epithelial ovarian cancer

  2021cites this paper
• Transcriptomics reveals in vivo efficacy of PARP inhibitor combinatorial synergy with platinum-based chemotherapy in human non-small cell lung carcinoma models

  2021cites this paper
• Targeting DNA repair pathway in cancer: Mechanisms and clinical application

  2021cites this paper
• PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review.

  2021cites this paper
• ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium

  2020cites this paper
• Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy

  2020cites this paper
• Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach

  2020cites this paper
• The PARP inhibitor olaparib (LynparzaTM) has shown an acceptable toxicity profile as monotherapy at doses up to 400 mg twice daily with encouraging signs of anti-tumor activity, especially in BRCA mutation carriers. Based on its mode of action, olaparib

  2020cites this paper
• Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors

  2020cites this paper
• Radiation-induced synthetic lethality: combination of poly(ADP-ribose) polymerase and RAD51 inhibitors to sensitize cells to proton irradiation

  2019cites this paper
• Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers

  2019cites this paper
• Mapping genetic interactions in cancer: a road to rational combination therapies

  2019cites this paper
• Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1)

  2019cites this paper
• ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.

  2019cites this paper
• Advances and perspectives of PARP inhibitors

  2019cites this paper
• NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells

  2019cites this paper
• Multifunctional APJ Pathway Promotes Ovarian Cancer Progression and Metastasis

  2019cites this paper
• Aberrations in DNA repair pathways in cancer and therapeutic significances.

  2019cites this paper
• Combination of PARP inhibitor and temozolomide to suppress chordoma progression

  2019cites this paper
• A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer

  2019cites this paper
• Double‐barreled gun: Combination of PARP inhibitor with conventional chemotherapy

  2018cites this paper
• New therapeutic strategies to treat human cancers expressing mutant p53 proteins

  2018cites this paper
• Clinical Utility of Poly (ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer

  2018cites this paper
• Impaired DNA double‐strand breaks repair by kinesin family member 4A inhibition renders human H1299 non‐small‐cell lung cancer cells sensitive to cisplatin

  2018cites this paper
• Identification of amentoflavone as a potent highly selective PARP-1 inhibitor and its potentiation on carboplatin in human non-small cell lung cancer.

  2018cites this paper
• Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.

  2017cites this paper
• Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ

  2017cites this paper
• Drugging the Cancers Addicted to DNA Repair

  2017cites this paper
• Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer

  2017cites this paper
• Comparative molecular profiling of HPV‐induced squamous cell carcinomas

  2017cites this paper
• PARP inhibitors as precision medicine for cancer treatment

  2017cites this paper
• Inhibition of PARP1 activity enhances chemotherapeutic efficiency in cisplatin-resistant gastric cancer cells.

  2017cites this paper
• Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property

  2017cites this paper
• BRCAness revisited

  2016cites this paper
• Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma

  2016cites this paper
• PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair

  2016cites this paper
• EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis

  2016cites this paper
• Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic

  2016cites this paper
• APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.

  2016cites this paper
• Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer – A Case Report

  2015cites this paper
• MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells.

  2015cites this paper
• Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines

  2015cites this paper
• DNA Repair Endonucleases

  2015cites this paper
• The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC

  2015cites this paper
• Elemental bioimaging of Cisplatin in Caenorhabditis elegans by LA-ICP-MS.

  2015cites this paper
• Altered expression profile of apoptosis-related molecules correlated with clinicopathological factors in non-small-cell lung cancer.

  2015cites this paper
• New therapeutic perspectives in CCDC6 deficient lung cancer cells

  2015cites this paper
• Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells

  2015cites this paper
• Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.

  2015cites this paper
• Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.

  2015cites this paper
• Influence of PJ34 on the genotoxicity induced by melphalan in human multiple myeloma cells

  2015cites this paper
• IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and dna repair associated molecules

  2015cites this paper
• A new arylbenzofuran derivative functions as an anti-tumour agent by inducing DNA damage and inhibiting PARP activity

  2015cites this paper
• PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.

  2015cites this paper
• Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells

  2015cites this paper
• New paradigms in the repair of oxidative damage in human genome: mechanisms ensuring repair of mutagenic base lesions during replication and involvement of accessory proteins

  2015cites this paper
• ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency.

  2014cites this paper
• ATRPathwayInhibitionIsSyntheticallyLethalinCancerCells with ERCC1 Deficiency

  2014cites this paper
• DNA repair pathways and their therapeutic potential in lung cancer

  2014cites this paper
• The role of DNA repair pathways in cisplatin resistant lung cancer.

  2014cites this paper
• Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors

  2014cites this paper
• Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer

  2014cites this paper
• A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer

  2013cites this paper
• Ligand modulation of a dinuclear platinum compound leads to mechanistic differences in cell cycle progression and arrest.

  2013cites this paper
• Customizing chemotherapy in thoracic malignancies based on ERCC1 expression

  2013cites this paper
• Synthetic lethality and functional study of DNA repair defects in ERCC1-deficient non-small-cell lung cancer

  2013cites this paper
• Oncotargets and Therapy Dovepress Combined Olaparib and Oxaliplatin Inhibits Tumor Proliferation and Induces G 2 /m Arrest and Γ-h2ax Foci Formation in Colorectal Cancer

  year unknowncites this paper